OA10499A - Guanine derivative - Google Patents

Guanine derivative Download PDF

Info

Publication number
OA10499A
OA10499A OA70051A OA70051A OA10499A OA 10499 A OA10499 A OA 10499A OA 70051 A OA70051 A OA 70051A OA 70051 A OA70051 A OA 70051A OA 10499 A OA10499 A OA 10499A
Authority
OA
OAPI
Prior art keywords
hydrochloride
valaciclovir
crystalline
valaciclovir hydrochloride
crystalline form
Prior art date
Application number
OA70051A
Other languages
English (en)
Inventor
Barry Howard Carter
Peter Gregory Varlashkin
Richard Augustus Winnike
Grubb William Bayne Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Jane Muse Partin
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of OA10499A publication Critical patent/OA10499A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
OA70051A 1995-01-20 1997-07-16 Guanine derivative OA10499A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
OA10499A true OA10499A (en) 2002-04-10

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70051A OA10499A (en) 1995-01-20 1997-07-16 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (fa)
EP (1) EP0804436B1 (fa)
JP (1) JP3176633B2 (fa)
KR (1) KR100376074B1 (fa)
CN (1) CN1049893C (fa)
AP (1) AP662A (fa)
AR (1) AR002270A1 (fa)
AT (1) ATE302777T1 (fa)
AU (1) AU702794B2 (fa)
BG (1) BG63393B1 (fa)
BR (1) BR9606768A (fa)
CA (1) CA2210799C (fa)
CY (1) CY2531B1 (fa)
CZ (1) CZ297065B6 (fa)
DE (1) DE69635106T2 (fa)
DK (1) DK0804436T3 (fa)
EA (1) EA000364B1 (fa)
EE (1) EE03528B1 (fa)
ES (1) ES2248806T3 (fa)
FI (1) FI973063A7 (fa)
GB (1) GB9501178D0 (fa)
GE (1) GEP20001940B (fa)
HR (1) HRP960024B1 (fa)
HU (1) HU222993B1 (fa)
IL (1) IL116831A (fa)
IN (1) IN182468B (fa)
IS (1) IS2268B (fa)
NO (1) NO315558B1 (fa)
NZ (1) NZ298851A (fa)
OA (1) OA10499A (fa)
PL (1) PL182175B1 (fa)
RO (1) RO118693B1 (fa)
RS (1) RS49518B (fa)
SI (1) SI0804436T1 (fa)
SK (1) SK285329B6 (fa)
TR (1) TR199700656T1 (fa)
UA (1) UA46001C2 (fa)
UY (1) UY25779A1 (fa)
WO (1) WO1996022291A1 (fa)
ZA (1) ZA96449B (fa)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
JP4097698B2 (ja) * 1996-01-19 2008-06-11 グラクソ、グループ、リミテッド 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
MY133479A (en) * 2001-02-24 2007-11-30 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1436295A4 (en) * 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
PL371732A1 (en) * 2001-11-14 2005-06-27 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
HU222993B1 (hu) 2004-01-28
AU702794B2 (en) 1999-03-04
JP3176633B2 (ja) 2001-06-18
CA2210799C (en) 2008-06-10
YU3396A (sh) 1998-12-23
RO118693B1 (ro) 2003-09-30
IS4527A (is) 1997-07-15
ZA96449B (en) 1996-08-07
HRP960024B1 (en) 2005-08-31
EP0804436A1 (en) 1997-11-05
TR199700656T1 (xx) 1998-03-21
EA000364B1 (ru) 1999-06-24
RS49518B (sr) 2006-10-27
SK96597A3 (en) 1998-02-04
UA46001C2 (uk) 2002-05-15
SI0804436T1 (sl) 2006-02-28
AR002270A1 (es) 1998-03-11
EE03528B1 (et) 2001-10-15
HUP9801836A2 (hu) 1999-05-28
IN182468B (fa) 1999-04-17
NO315558B1 (no) 2003-09-22
KR100376074B1 (ko) 2003-06-02
GEP20001940B (en) 2000-02-05
IL116831A (en) 1998-10-30
IL116831A0 (en) 1996-05-14
KR19980701525A (ko) 1998-05-15
PL182175B1 (pl) 2001-11-30
US6107302A (en) 2000-08-22
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
CZ229497A3 (en) 1997-12-17
IS2268B (is) 2007-07-15
FI973063L (fi) 1997-09-18
ES2248806T3 (es) 2006-03-16
NO973326L (no) 1997-09-16
EA199700124A1 (ru) 1997-12-30
NO973326D0 (no) 1997-07-18
BR9606768A (pt) 1997-12-30
EP0804436B1 (en) 2005-08-24
AP9701058A0 (en) 1997-10-31
MX9705462A (es) 1997-10-31
UY25779A1 (es) 2000-08-21
PL321326A1 (en) 1997-12-08
CA2210799A1 (en) 1996-07-25
HRP960024A2 (en) 1997-10-31
JPH11503718A (ja) 1999-03-30
EE9700175A (et) 1998-02-16
HUP9801836A3 (en) 1999-06-28
SK285329B6 (sk) 2006-11-03
DE69635106T2 (de) 2006-06-08
AP662A (en) 1998-08-19
AU4453996A (en) 1996-08-07
DE69635106D1 (de) 2005-09-29
FI973063A7 (fi) 1997-09-18
GB9501178D0 (en) 1995-03-08
CY2531B1 (en) 2006-04-12
ATE302777T1 (de) 2005-09-15
DK0804436T3 (da) 2005-12-27
CN1179159A (zh) 1998-04-15
CZ297065B6 (cs) 2006-08-16
NZ298851A (en) 1999-01-28
FI973063A0 (fi) 1997-07-18
BG101833A (bg) 1998-04-30
WO1996022291A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
OA10499A (en) Guanine derivative
OA10500A (en) Valaciclovir tablets containing colloidal silicon dioxide
EP1071693B1 (en) Novel crystalline forms of an antiviral benzimidazole compound
CA2327495C (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)-1h-benzimidazole
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005462A (en) Derived from guan
CN115385931A (zh) 多替拉韦钠的多晶型物及其制备方法
HK1032060B (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl)-1h-benzimidazole
MXPA00009734A (en) Novel crystalline forms of an antiviral benzimidazole compound